Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT00124449




Registration number
NCT00124449
Ethics application status
Date submitted
30/06/2005
Date registered
28/07/2005
Date last updated
7/04/2015

Titles & IDs
Public title
Study of Abatacept Versus Placebo to Assess the Prevention of Rheumatoid Arthritis (RA) in Adult Patients
Scientific title
A Phase II Study of Abatacept Versus Placebo to Assess the Prevention of Rheumatoid Arthritis (RA) in Adult Patients With Undifferentiated Arthritis Who Are at High Risk for the Development of RA
Secondary ID [1] 0 0
IM101-046
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Arthritis, Rheumatoid 0 0
Condition category
Condition code
Musculoskeletal 0 0 0 0
Osteoarthritis
Inflammatory and Immune System 0 0 0 0
Rheumatoid arthritis

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Abatacept
Treatment: Drugs - placebo

Active comparator: 1 -

Placebo comparator: 2 -


Treatment: Drugs: Abatacept
solution, intravenous injection, monthly, 169 days

weight based:

\<60 kg = 500 mg

60 to 100 kg = 750 mg

\>100 kg = 1 g

Treatment: Drugs: placebo
solution, intravenous injection, 0 mg, monthly, 169 days
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Number of Participants With a Diagnosis of Rheumatoid Arthritis (RA) by American Rheumatism Association (ARA) Criteria and/or Discontinued Due to Lack of Efficacy
Timepoint [1] 0 0
12 months
Secondary outcome [1] 0 0
Number of Participants With a Diagnosis of RA by 1987 ARA Criteria and/or Discontinued Due to Lack of Efficacy
Timepoint [1] 0 0
24 months
Secondary outcome [2] 0 0
Number of Participants With Undifferentiated Inflammatory Arthritis (UA) Who Develop Another Rheumatic Disease
Timepoint [2] 0 0
12 months, 24 months
Secondary outcome [3] 0 0
Change From Baseline in Radiographic Erosion and Joint Space Narrowing Score at 6 Months, 12 Months, and 24 Months
Timepoint [3] 0 0
Baseline, 6 months, 12 months, 24 months
Secondary outcome [4] 0 0
Change From Baseline in Total Erosion, Edema, Synovitis Scores at 6 Months, 12 Months, and 24 Months
Timepoint [4] 0 0
Baseline, 6 months, 12 months, 24 months
Secondary outcome [5] 0 0
Number of Participants With Persistent Symptomatic Clinical Synovitis
Timepoint [5] 0 0
6, 12, and 24 months
Secondary outcome [6] 0 0
Short Form-36 (SF-36) Physical and Mental Component Summary (PCS and MCS) Scores - Mean Change From Baseline
Timepoint [6] 0 0
6 months, 12 months, 24 months
Secondary outcome [7] 0 0
Change From Baseline in Cytokine Levels and Second Generation Anti-cyclic Citrullinated Peptide (Anti-CCP2) Antibodies at 6 Months, 12 Months, and 24 Months
Timepoint [7] 0 0
Baseline, 6 Months, 12 months, 24 months
Secondary outcome [8] 0 0
Number of Participants With Anti-CCP2 Positive and/or Rheumatoid Factor (RF) Positive Over Time
Timepoint [8] 0 0
Day 1, 6 months, 12 months, 24 months
Secondary outcome [9] 0 0
Frequency of Human Leukocyte Antigen (HLA) Typing
Timepoint [9] 0 0
Day 1
Secondary outcome [10] 0 0
DAS 28 C Reactive Protein (CRP) Score - Mean Change From Baseline
Timepoint [10] 0 0
6 months, 12 months, 24 months
Secondary outcome [11] 0 0
Number of Participants With a DAS 28 (CRP) Score of =3.2 (Low Disease Activity) or <2.6 (in Remission)
Timepoint [11] 0 0
6 months, 12 months, 24 months
Secondary outcome [12] 0 0
Number of Subjects With Health Assessment Questionnaire (HAQ) Disability Index Response
Timepoint [12] 0 0
6 months, 12 months, 24 months
Secondary outcome [13] 0 0
Overall Safety - Adverse Events (AEs), Serious AEs, and Deaths
Timepoint [13] 0 0
Throughout the treatment period (6 months)
Secondary outcome [14] 0 0
Number of Participants With Positive Responses for Serum Levels of Abatacept-specific Antibodies
Timepoint [14] 0 0
Up to 12 months

Eligibility
Key inclusion criteria
* Diagnosis of undifferentiated arthritis
* Clinical synovitis of two or more joints
* At least one but not more than three of the criteria for diagnosis of RA (1987).
* No prior disease modifying anti-rheumatic drugs (DMARDs)/biologics.
* Duration of disease must be 18 months or less.
* Positive for antibodies against cyclic citrullinated peptides.
Minimum age
18 Years
Maximum age
75 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Women of child bearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy.
* Active vasculitis of a major organ system.
* Severe or recurrent bacterial infection.
* History of cancer in the last five years except certain skin cancers.
* Herpes zoster that resolved less than 2 months prior to enrollment

Study design
Purpose of the study
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/02/2005
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/04/2008
Sample size
Target
Accrual to date
Final
56
Recruitment in Australia
Recruitment state(s)
QLD,VIC,WA
Recruitment hospital [1] 0 0
Local Institution - Cairns
Recruitment hospital [2] 0 0
Local Institution - Clayton
Recruitment hospital [3] 0 0
Local Institution - Malvern
Recruitment hospital [4] 0 0
Local Institution - Shenton Park
Recruitment postcode(s) [1] 0 0
- Cairns
Recruitment postcode(s) [2] 0 0
- Clayton
Recruitment postcode(s) [3] 0 0
- Malvern
Recruitment postcode(s) [4] 0 0
- Shenton Park
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Illinois
Country [6] 0 0
United States of America
State/province [6] 0 0
Indiana
Country [7] 0 0
United States of America
State/province [7] 0 0
Louisiana
Country [8] 0 0
United States of America
State/province [8] 0 0
Maryland
Country [9] 0 0
United States of America
State/province [9] 0 0
Minnesota
Country [10] 0 0
United States of America
State/province [10] 0 0
North Carolina
Country [11] 0 0
United States of America
State/province [11] 0 0
Oklahoma
Country [12] 0 0
United States of America
State/province [12] 0 0
Pennsylvania
Country [13] 0 0
United States of America
State/province [13] 0 0
South Carolina
Country [14] 0 0
United States of America
State/province [14] 0 0
Texas
Country [15] 0 0
United States of America
State/province [15] 0 0
Virginia
Country [16] 0 0
Belgium
State/province [16] 0 0
Bruxelles
Country [17] 0 0
Belgium
State/province [17] 0 0
Leuven
Country [18] 0 0
France
State/province [18] 0 0
Paris
Country [19] 0 0
France
State/province [19] 0 0
Strasbourg Cedex
Country [20] 0 0
Germany
State/province [20] 0 0
Berlin
Country [21] 0 0
Germany
State/province [21] 0 0
Dresden
Country [22] 0 0
Germany
State/province [22] 0 0
Hamburg
Country [23] 0 0
Germany
State/province [23] 0 0
Hannover
Country [24] 0 0
Germany
State/province [24] 0 0
Heidelberg
Country [25] 0 0
Italy
State/province [25] 0 0
Bari
Country [26] 0 0
Italy
State/province [26] 0 0
Ferrara
Country [27] 0 0
Italy
State/province [27] 0 0
Milano
Country [28] 0 0
Mexico
State/province [28] 0 0
Distrito Federal
Country [29] 0 0
Mexico
State/province [29] 0 0
Guanajuato
Country [30] 0 0
Mexico
State/province [30] 0 0
Jalisco
Country [31] 0 0
Mexico
State/province [31] 0 0
Michioacan
Country [32] 0 0
Puerto Rico
State/province [32] 0 0
Ponce
Country [33] 0 0
Spain
State/province [33] 0 0
A Coruna
Country [34] 0 0
Spain
State/province [34] 0 0
Barcelona
Country [35] 0 0
Spain
State/province [35] 0 0
Madrid
Country [36] 0 0
Spain
State/province [36] 0 0
Oviedo
Country [37] 0 0
Spain
State/province [37] 0 0
Sevilla
Country [38] 0 0
United Kingdom
State/province [38] 0 0
Merseyside
Country [39] 0 0
United Kingdom
State/province [39] 0 0
North Yorkshire

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Bristol-Myers Squibb
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to assess if Abatacept given for six months will prevent rheumatoid arthritis (RA) in patients who are at risk for the development of RA in comparison to placebo. High risk patients are defined as those having a positive laboratory test for anti-cyclic citrullinated peptide (anti-CCP2).
Trial website
https://clinicaltrials.gov/study/NCT00124449
Trial related presentations / publications
Emery P, Durez P, Dougados M, Legerton CW, Becker JC, Vratsanos G, Genant HK, Peterfy C, Mitra P, Overfield S, Qi K, Westhovens R. Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial). Ann Rheum Dis. 2010 Mar;69(3):510-6. doi: 10.1136/ard.2009.119016. Epub 2009 Nov 23. Erratum In: Ann Rheum Dis. 2011 Aug;70(8):1519.
Public notes

Contacts
Principal investigator
Name 0 0
Bristol-Myers Squibb
Address 0 0
Bristol-Myers Squibb
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT00124449